CAS: 687-47-8; (S)-Ethyl Lactate

相似化合物

2051-96-9 7699-00-5 13650-70-9

上下游产品

CAS号617-35-6 丙酮酸乙酯 | CAS号174417-26-6 ethyl (2S)-2-[(... | CAS号64-17-5 乙醇 | CAS号79-33-4 L-(+)-乳酸 | CAS号73208-70-5 2-(TETRAHYDRO-P... | CAS号75-03-6 碘乙烷 | CAS号13076-17-0 D-丙交酯 | CAS号271244-06-5 (R)-ethyl 2-((R... | CAS号13031-04-4 二氢-4,4-二甲基-2,3-呋喃二酮 | CAS号6342-56-9 丙酮醛缩二甲醇 | CAS号57057-80-4 L-(-)-O-甲苯磺酰乳酸乙酯 | CAS号46755-94-6 (S)-(-)-1,1-二苯基... | CAS号37493-14-4 (R)-2-氯丙-1-醇 | CAS号146432-17-9 (2S)-2-hydroxy-... | CAS号4254-14-2 (|R|)-(-)-1,2-丙二醇 | CAS号4254-15-3 (S)-1,2-丙二醇 | CAS号41918-08-5 S)-(-)-2-甲氧基丙酸乙酯 | CAS号18449-60-0 sec-butyl lactate | CAS号18672-09-8 ethyl (2R)-2-(4...

丙酮酸乙酯置于氢气,溶剂黄146,奎尼丁体系中,19.84 °C,100.0 Kpa 条件下,以90%的收率获得产物
参考文献:介孔二氧化硅负载铂催化剂在丙酮酸乙酯对映选择性加氢中的应用
标题:介孔二氧化硅负载铂催化剂在丙酮酸乙酯对映选择性加氢中的应用
摘要:研发了负载在介孔二氧化硅(pt/ M-Sio 2)上的pt催化剂在丙酮酸乙酯的对映选择性加氢中的催化性能.采用不同的m-Sio 2载体和金鸡纳生物碱,改变h 2压力,研究了介孔二氧化硅(M-Sio 2)的孔结构,手性改性剂类型和h 2压力对催化性能的影响.mcm-41,Sba-15,Kit-6 和 Mcf 的使用揭示了m-Sio 2的特征孔结构和尺寸支持显着影响活性和对映选择性.手性改性剂通过 Mcf 载体的大介孔轻松扩散,使 Pt/mcf 表现出优异的性能.金鸡纳生物碱修饰的 Pt 催化剂的效率比较表明,在环境 H 2压力下,Qn 和 Qd 比 Cd 和 Cn 具有更高的性能.金鸡纳生物碱对对映选择性的影响明显取决于h 2压力.金鸡纳生物碱修饰的pt/ M-Sio 2在不同的h 2压力下表现出优于相应的pt/al 2 O 3的对映选择性.这些结果意味着m-Sio
DOI:10.1016/j.Cattod.2020.06.010

专利信息

专利号:US-9809566-B2
优先权日:2012-09-06
标题:Organocatalytic process for asymmetric synthesis of decanolides
发明人：RAWAT VARUN; DEY SOUMEN; SHELKE ANIL MARUTI; SURYAVANSHI GURUNATH MALLAPPA; SUDALAI ARUMUGAM
权利人:COUNCIL SCIENT IND RES
摘要:The present invention discloses organocatalytic process for asymmetric synthesis of highly enantioselective decanolide compounds in high yield with >99% ee. Further, the present invention disclose cost effective, improved organocatalytic process for asymmetric synthesis of highly enantioselective decanolides compounds from non-chiral, cheap, easily available raw materials.

专利号:US-4412958-A
优先权日:1981-10-16
标 题:Stereospecific synthesis of 5-phenyl-2S-pentanol
发明人：CUE JR BERKELEY W; MOORE BERNARD S
权利人:PFIZER
摘要:5-Phenyl-2S-pentanol is synthesized stereospecifically from S ethyl lactate. The method provides easily purified 5-phenyl-2S-pentanol useful in the synthesis of central nervous system active (CNS) agents such as levonantradol.

专利号:US-9771377-B2
优先权日:2012-12-21
标 题 :Synthesis of FR901464 and analogs with antitumor activity
发明人：KOIDE KAZUNORI; OSMAN SAMI SAIF ELDIN ALI
权利人:UNIV OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
摘要:The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.

专利号:WO-2014097257-A1
优先权日:2012-12-21
标 题:A method of preparation of (1'r,3r,4r)-4-acetoxy-3-(1'-(tert-butyldimethylsilyloxy)ethyl)-2-azetidinone, a precursor for carbapenem antibiotics synthesis
发明人：GRZESZCZYK BARBARA; STECKO SEBASTIAN; FURMAN BARTÅ?OMIEJ; CHMIELEWSKI MAREK
权利人:INST CHEMII ORGANICZNEJ PAN
摘要:The subject of the present invention is a method of preparation of (1'R,3R,4R)-4-acetoxy-3-(1'- (tert-butyl-dimethylsilyloxy)ethyl)-2-azetidinone defined by the formula (1) which is a basic chiral building block in the synthesis of carbapenem antibiotics.

专利号:US-2009162290-A1
优先权日:2005-09-09
标 题 :Method for the synthesis of penta-pendant enantiomer-pure chelators and process for therapeutically active bioconjugates preparation by a covalent binding thereof
发明人：BENES IVAN; CIHELNIK SIMON; DROZ LADISLAV; SRAMEK MARTIN
权利人:THERAPHARM GMBH
摘要:The present invention provides a method for synthesis and binding methods of pentapendant enantiomer-pure chelators of formula (VII) wherein R 1 , R 2 , R 3 , R 4 are groups forming an adequate enantiomer of the chelator; and X 1 -X 5 , Y 1 -Y 5 , Z 1 -Z 5 each individually forming pendant chelating groups.

专利号:US-6869973-B2
优先权日:2000-06-22
标题:Nitrosated and nitrosylated taxanes, compositions and methods of use
发明人：GARVEY DAVID S; LETTS L GORDON; LIN CHIA-EN; RICHARDSON STEWART K; WANG TIANSHENG
权利人:NITROMED INC
摘要:The present invention describes novel nitrosated and/or nitrosylated taxanes, and novel compositions comprising at least one nitrosated and/or nitrosylated taxane, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The present invention also provides novel compositions comprising at least one taxane and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The compounds and compositions of the present invention can also be bound to a matrix. The present invention also provides methods for treating or preventing cardiovascular diseases and disorders, autoimmune diseases, pathological conditions resulting from abnormal cell proliferation, polycystic kidney disease, inflammatory disease, preserving organs and/or tissues or to inhibit wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis, by administering nitrosated and/or nitrosylated taxane or parent taxanes in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions.